List view / Grid view
17 July 2024 | By Eurofins Discovery
Join this webinar to hear from Eurofins Discovery on the latest offerings for drug-drug interaction assessments using CRISPR KO/KI MDCKII cell lines
Researchers show that proteins released from the brain during migraine with aura are transported by CSF to pain-signalling nerves.
A new approach called reverse metabolomics has discovered molecules that may serve as a biomarker or a therapeutic target for IBD.
25 July 2023 | By CN Bio
The webinar will explore primary concerns in drug discovery development and why drugs fail.
Japanese study has identified three previously unknown membrane proteins in ovarian cancer, using a new detection method consisting of nanotechnology and imaging techniques.
19 May 2023 | By CN Bio
A discussion of the recently published paper, “Normalization of Organ-on-a-Chip Samples for Mass Spectrometry Based Proteomics and Metabolomics via Dansylation-based Assay,” and how the field can produce more replicable experiments.
Chinese researchers use a glycosidic-bond-based mass-spectrometry-cleavable cross-linker to analyse proteins in vivo.
16 March 2023 | By Eurofins Discovery Services
In this on-demand webinar, we present the most advanced label-free technologies in identifying successful hit series for Hit-to-Lead and Lead-Optimization programs.
Japanese researchers combine cutting edge mass spectrometry with software analysis to elucidate mRNA structure.
Discover everything pharmaceutical scientists need to know about solid form characterisation, starting with API selection.
Dr. Stokes, Associate Director Proteomics, discusses how proteomic studies can increase effectiveness, speed of target and biomarker identification.
Discover how Malvern Panalytical’s combination of analytical instrumentation and research services can take particle size analysis to the next level.
This Malvern Panalytical guide explores the use of Xray powder diffraction (XRPD) as a powerful tool to develop and improve pharmaceutical formulation.
Looking for solutions to resolve your unique challenges? We offer several customized products and services to move your discovery forward.
The molecules, called SGDGs, may lead to new ways to treat age-related neurological diseases.
